Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie důkazu koncepce pro SAR445088 u chronické zánětlivé demyelinizační polyneuropatie (CIDP)

27. října 2026 aktualizováno: Bioverativ, a Sanofi company

Fáze 2, multicentrická, otevřená, nerandomizovaná studie prokazující koncepci hodnotící účinnost, bezpečnost a snášenlivost SAR445088 u dospělých s chronickou zánětlivou demyelinizační polyneuropatií (CIDP)

Primary Objectives:

  • Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive
  • Part B:Long-term safety and tolerability of SAR445088 in CIDP

Secondary Objectives:

  • Part A:

    • Safety and tolerability of SAR445088 in CIDP
    • Immunogenicity of SAR445088
    • Efficacy of SAR445088 with overlapping SOC (SOC-Treated group)
  • Part B:

    • Durability of efficacy during long-term treatment with SAR445088 in CIDP
    • Long-term immunogenicity of SAR445088 in CIDP

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

The duration of the study for a participant will include:

Part A Screening period: up to 6 weeks. Treatment period: once successfully screened, enrolled participants will receive study intervention for 24 weeks.

Safety follow-up visit: participants who do not enroll (rollover) into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24, ie, approximately at Week 46.

Part B Treatment period (extension): for all groups, this period will consist of 52 weeks of treatment with SAR445088 (Weeks 24 to 76; Part A and B total treatment period of 76 weeks).

Safety follow-up visit: participants who do not enroll (rollover) into Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (Week 98).

Part C Treatment period: participants who complete Part B will be reassessed for continuing eligibility, defined as having successfully completed Part B (received IMP until the Week 76 visit and have responded to SAR445088 based on Investigator's medical judgement), with no new safety concerns. Eligible participants will be given the option of rolling into Part C, where they will continue receiving SAR445088 until end of study.

End of study has been defined as the last safety follow-up visit for the last patient which occurs 22 weeks after last dose.

In addition, there is a follow-up call 56 weeks ±14 days after last dose to confirm negative result of urine pregnancy test for women of childbearing potential who are participating in the study, or to query male participants regarding pregnancy of partners who are women of childbearing potential.

Typ studie

Intervenční

Zápis (Aktuální)

98

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Bordeaux, Francie, 33076
        • Investigational Site Number : 2500003
      • Le Kremlin-Bicêtre, Francie, 94270
        • Investigational Site Number : 2500005
      • Marseille, Francie, 13885
        • Investigational Site Number : 2500001
      • Nice, Francie, 06001
        • Investigational Site Number : 2500002
      • Amsterdam, Holandsko, 1105 AZ
        • Investigational Site Number : 5280001
    • Genova
      • Genoa, Genova, Itálie, 16132
        • Investigational Site Number : 3800003
    • Milano
      • Milan, Milano, Itálie, 20132
        • Investigational Site Number : 3800001
      • Rozzano, Milano, Itálie, 20089
        • Investigational Site Number : 3800005
    • Roma
      • Rome, Roma, Itálie, 00168
        • Investigational Site Number : 3800002
    • Quebec
      • Gatineau, Quebec, Kanada, J8Y 1W2
        • Investigational Site Number : 1240001
      • Québec, Quebec, Kanada, G1J 1Z4
        • Investigational Site Number : 1240002
      • Düsseldorf, Německo, 40225
        • Investigational Site Number : 2760001
      • Göttingen, Německo, 37075
        • Investigational Site Number : 2760002
      • Tübingen, Německo, 72076
        • Investigational Site Number : 2760004
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polsko, 20-954
        • Investigational Site Number : 6160001
    • California
      • Los Angeles, California, Spojené státy, 90033
        • USC Norris Comprehensive Cancer Center- Site Number : 8400004
      • Orange, California, Spojené státy, 92868
        • University of California Irvine - Manchester Pavilion- Site Number : 8400002
    • Kansas
      • Fairway, Kansas, Spojené státy, 66205
        • University of Kansas Clinical Research Center- Site Number : 8400003
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55455
        • M Health Fairview University of Minnesota Medical Center - East Bank- Site Number : 8400006
    • New York
      • New York, New York, Spojené státy, 10032
        • Columbia University Irving Medical Center- Site Number : 8400005
      • Belgrade, Srbsko, 11000
        • Investigational Site Number : 6880001
      • Niš, Srbsko, 18000
        • Investigational Site Number : 6880003
      • Fuzhou, Čína, 350001
        • Investigational Site Number : 1560002
      • Shanghai, Čína, 200040
        • Investigational Site Number : 1560001
      • Wuhan, Čína, 430030
        • Investigational Site Number : 1560004
      • Valencia, Španělsko, 46026
        • Investigational Site Number : 7240003
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Španělsko, 08035
        • Investigational Site Number : 7240002
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Španělsko, 08041
        • Investigational Site Number : 7240001

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Adults ≥18 years of age at the time of signing the informed consent.
  • Documented definite or probable diagnosis of CIDP (typical CIDP, pure motor CIDP, or Lewis-Sumner Syndrome) according to the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) Task Force first revision.
  • Belonging to one of the following three groups: standard-of-care (SOC)-Treated, SOC-Refractory or SOC-Naive, as defined below.
  • SOC-Treated (all criteria a-c must be met): a) Documented evidence of objective response to SOC, with clinically meaningful improvement. Clinically meaningful improvement is defined as one of the following: ≥1-point decrease in adjusted INCAT score, ≥4 points increase in RODS total score, ≥3 points increase in MRC Sum score, ≥8 kilopascal improvement in mean grip strength (one hand), or an equivalent improvement based on information documented in medical records and per the PI's judgement. b) Must be on stable SOC therapy, defined as no change greater than 10% in frequency or dose of immunoglobulin therapy or corticosteroids within 8 weeks prior to screening, remaining at stable SOC therapy until the time of first SAR445088 dosing. c) Evidence of clinically meaningful deterioration on interruption or dose reduction of SOC therapy within 24 months prior to screening, determined by clinical examination or medical records. Clinically meaningful deterioration is defined as one of the following: ≥1-point increase in adjusted INCAT score, decrease in RODS total score ≥4 points, decrease in MRC Sum score ≥3, mean grip strength worsening of ≥8 kilopascals (one hand), or an equivalent deterioration based on information from medical records and at the PI's judgement.
  • SOC-Refractory (all criteria a-d must be met): a) Evidence of failure or inadequate response to SOC defined as no clinically meaningful improvement and persistent INCAT score ≥2 after treatment for a minimum of 12 weeks on SOC prior to screening. A clinically meaningful improvement is defined as one of the following: ≥1-point decrease in adjusted INCAT score, increase in RODS total score ≥4 points, increase in MRC Sum score ≥3, mean grip strength improvement of ≥8 kilopascals (one hand), or equivalent improvement based on information from medical records and at the PI's judgement.

Or

  • Unable to receive or continue treatment with immunoglobulins or corticosteroids due to side effects.
  • b) Patient has not received immunoglobulins (IVIg or SCIg) within 12 weeks prior to screening. c) Certain immunosuppressant drugs are allowed in this group if taken for ≥6 months and at a stable dose for ≥3 months prior to screening: azathioprine, methotrexate, mycophenolate mofetil and cyclosporine. Oral corticosteroids are allowed if on a stable dose of <20 mg/day of prednisone (or equivalent dose for other oral corticosteroids) for ≥3 months prior to screening. d) INCAT score: 2-9 (a score of 2 should be exclusively from leg disability component of INCAT).
  • SOC-Naive (all criteria a-c must be met): a) Participants without previous treatment for CIDP or participants who received immunoglobulins (IVIg or SCIg) or corticosteroids but were stopped for reasons other than lack of response or side effects. b) Not treated with immunoglobulins (IVIg or SCIg) or corticosteroids for at least 6 months prior to screening. c) INCAT score: 2-9 (a score of 2 should be exclusively from leg disability component of INCAT.
  • Documented vaccinations against encapsulated bacterial pathogens given within 5 years of enrollment or initiated a minimum of 14 days prior to first dose
  • A female participant must use a double contraception method including a highly effective method of birth control from inclusion and up to 52 weeks plus 30 days after the last study dose and agree not to donate eggs, ova or oocytes during this period.
  • A female participant must have a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours before the first dose of study intervention.
  • Male participants, whose partners are of childbearing potential must accept to use, during sexual intercourse, a double contraceptive method according to the following: condom plus an additional highly effective contraception
  • Male participants must have agreed not to donate sperm during the intervention and up to 52 weeks after the last dose.
  • Capable of giving signed informed consent

Exclusion Criteria:

  • Polyneuropathy of other causes, including but not limited to hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS syndrome, lumbosacral radiculoplexus neuropathy, pure sensory CIDP and acquired demyelinating symmetric (DADS) neuropathy (also known as distal CIDP).
  • Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments.
  • Poorly controlled diabetes (HbA1c >7%).
  • Serious infections requiring hospitalization within 30 days prior to screening and any active infection requiring treatment during screening.
  • Clinical diagnosis of SLE.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any hypersensitivity reaction to SAR445088 or its components or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody.
  • Participants with a history of suicidality in the six months prior to screening or currently at risk of committing suicide.
  • Presence of conditions (medical history or laboratory assessments) that may predispose the participant to excessive bleeding or increased risk of infection.
  • Evidence of CIDP relapse within 6 weeks after receiving a vaccination.
  • Recent or planned major surgery that could confound the results of the trial or put the participant at undue risk.
  • Treatment with plasma exchange within 12 weeks prior to screening.
  • Prior treatment with rituximab or ocrelizumab in the 6 months prior to SAR445088 dosing or until return of B-cell counts to normal levels, whichever is longer.
  • Immunosuppressive/chemotherapeutic medications such as azathioprine, methotrexate, cyclophosphamide, cyclosporine, mycophenolate mofetil, tacrolimus, interferon, TNF-alpha inhibitor: within 6 months prior to dosing (except for some cases as indicated in the SOC-Refractory group).
  • Treatment (any time) with highly immunosuppressive/chemotherapeutic medications with sustained effects, eg, mitoxantrone, alemtuzumab, cladribine.
  • Treatment (any time) with total lymphoid irradiation or bone marrow transplantation.
  • Use of any specific complement system inhibitor (eg, eculizumab) within 12 weeks or 5 times the half-life of the product, whichever is longer, prior to screening.
  • Pregnant (defined as positive β-HCG blood test) or lactating females.
  • Positive result on any of the following tests: hepatitis B surface (HBsAg) antigen, anti-hepatitis B core antibodies (anti-HBc Ab)-unless anti-hepatitis B surface antibodies (anti-HBs Ab) are also positive , indicating natural immunity-, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 antibodies).
  • Evidence of IgG4 autoantibodies against paranodal proteins (NF155 and CNTN1).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: SOC-Refractory Initial Dose

Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately (~)at Week 46).

Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they will not continue in Part C.

Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.

Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose.

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Experimentální: SOC-Refractory Low Dose

Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).

Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility and will be given the option to roll into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C.

Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study.

Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose.

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Experimentální: SOC-Treated Initial Dose

Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects of SOC therapy; Weeks 13-24: SAR445088 given.

Participants who do not enroll into Part B will attend final safety follow-up visit at 22 weeks after Week 24 (~Week 46).

Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C.

Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study.

Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit at 22 weeks after the last SAR445088 dose.

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Experimentální: SOC-Naive

Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).

Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose (approximately week 98) if they do not continue in Part C.

Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose.

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Experimentální: SOC-Treated Low Dose

Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects SOC therapy; Weeks 13-24: SAR445088. Participants who do not enroll into Part B will attend a final safety follow-up visit that will take place 22 weeks after Week 24 (~Week 46).

Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility, will be given the option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C.

Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue at any time in Part C will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose.

Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Part A: Standard of Care-Treated Only: Percentage of Participants With Relapse After Withdrawal of Standard of Care During the Riliprubart Treatment Period
Časové okno: From Day 1 up to Week 24

The relapse was defined as >=1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Day 1 up to Week 24
Part A: Standard of Care-Refractory Only: Percentage of Participants With Response During the Riliprubart Treatment Period
Časové okno: From Day 1 up to Week 24

The response was defined as >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Day 1 up to Week 24
Part A: Standard of Care-Naïve Only: Percentage of Participants With Response During the Riliprubart Treatment Period
Časové okno: From Day 1 up to Week 24

The response was defined as >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Day 1 up to Week 24
Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Časové okno: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks

An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant temporally associated with use of study treatment, whether or not considered related to study treatment. An SAE is defined as any AE that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is a suspected transmission of any infectious agent via an authorized medicinal product or other situations where medical or scientific judgment exercised by Investigator. The Investigator assessed severity for each AE and SAE using NCI CTCAE Version 5.0, that is, Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death). TEAEs are defined as AEs that developed, worsened or became serious during treatment-emergent (TE) period (Part A: 24 weeks and Part B: 52 weeks).

From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Part A: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events
Časové okno: From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks

An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE is defined as any AE that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is a suspected transmission of any infectious agent via an authorized medicinal product or other situations where medical or scientific judgment exercised by the Investigator. The Investigator assessed severity for each AE and SAE using NCI CTCAE Version 5.0, that is, Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death). The TEAEs are defined as AEs that developed, worsened or became serious during TE period (Part A: 24 weeks).

From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
Part A: Number of Participants With Anti-Drug Antibodies (ADA) for Riliprubart During the Treatment and Follow-up Period
Časové okno: From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks

Treatment-induced ADAs were defined as participants with ADAs that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADAs were defined as participants with pre-existing ADAs that were boosted during the TE period to a significantly higher titer than the baseline. A 2-fold serial dilution schema was used during titration, so at least a 4-fold increase was considered as significant.

From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
Part A (Standard of Care-Treated: Riliprubart Initial Dose Only): Percentage of Participants With Improvement During the Overlap Treatment Period
Časové okno: From Day 1 up to Week 12

Improvement was defined as a >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Day 1 up to Week 12
Part B (Standard of Care-Treated: Riliprubart Initial Dose Only): Percentage of Participants With Relapse-Free During the Treatment Extension Period
Časové okno: From Week 24 through Week 76, that is, Weeks 36, 48, 60 and 76

The relapse-free was defined as no increase in adjusted INCAT disability score >=2 points. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Week 24 through Week 76, that is, Weeks 36, 48, 60 and 76
Part B (Excluding Standard of Care-Treated: Riliprubart Low Dose): Percentage of Participants With Sustained Response During the Treatment Extension Period
Časové okno: From Week 24 through Week 76

The sustained response was defined as no increase in adjusted INCAT disability score >=2 points. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place.

From Week 24 through Week 76
Parts A and B: Number of Participants With Anti-Drug Antibodies for Riliprubart During the Entire Treatment and Follow-up Period
Časové okno: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks

Treatment-induced ADAs were defined as participants with ADAs that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADAs were defined as participants with pre-existing ADAs that were boosted during the TE period to a significantly higher titer than the baseline. A 2-fold serial dilution schema was used during titration, so at least a 4-fold increase was considered as significant.

From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Clinical Sciences & Operations, Sanofi

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

28. dubna 2021

Primární dokončení (Aktuální)

1. října 2025

Dokončení studie (Aktuální)

1. října 2025

Termíny zápisu do studia

První předloženo

1. prosince 2020

První předloženo, které splnilo kritéria kontroly kvality

1. prosince 2020

První zveřejněno (Aktuální)

8. prosince 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

27. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • PDY16744
  • 2020-004006-54 (Číslo EudraCT)
  • U1111-1246-7023 (Identifikátor registru: ICTRP)
  • 2024-512345-16-00 (Identifikátor registru: CTIS)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .